Combined angiotensin-converting enzyme inhibition and receptor blockade associate with increased risk of cardiovascular death in hemodialysis patients

Kidney International

Volumn 80, Issue 9, 2011, Pages 978-985

  Chan, Kevin E ^a   Ikizler, T Alp ^b   Gamboa, Jorge L ^b   Yu, Chang ^b   Hakim, Raymond M ^a   Brown, Nancy J ^b  

^a FRESENIUS MEDICAL CARE NORTH AMERICA   (United States)

^b VANDERBILT UNIVERSITY   (United States)

Author keywords

ACE inhibitors; angiotensin; chronic hemodialysis; chronic inflammation; oxidative stress

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDRALAZINE; LABETALOL; MINOXIDIL;

ADULT; ARTICLE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CAUSE OF DEATH; COHORT ANALYSIS; CONGESTIVE CARDIOMYOPATHY; DEATH; FEMALE; HEMODIALYSIS; HUMAN; HYPERKALEMIA; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; ORTHOSTATIC HYPOTENSION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; SURVIVAL;

EID: 80054761708     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2011.228     Document Type: Article

References (44)

1. Go AS, Chertow GM, Fan D et al. Chronic kidney disease and the risks of death cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296-1305.
2. Liu Y, Coresh J, Eustace JA et al. Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrition. JAMA 2004; 291: 451-459.
3. Holdaas H, Fellstrom B, Jardine AG et al. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet 2003; 361: 2024-2031.
4. Wanner C, Krane V, Marz W et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005; 353: 238-248.
5. Fellstrom BC, Jardine AG, Schmieder RE et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 2009; 360: 1395-1407.
6. ONTARGET Investigators Yusuf S, Teo KK, Pogue J et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 1547-1559.
7. Pfeffer MA, McMurray JJ, Velazquez EJ et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003; 349: 1893-1906.
8. Strauss MH, Hall AS. Angiotensin receptor blockers may increase risk of myocardial infarction: unraveling the ARB-MI paradox. Circulation 2006; 114: 838-854.
9. Yusuf S, Sleight P, Pogue J et al. Effects of an angiotensin- convertingenzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342: 145-153.
10. Baker WL, Coleman CI, Kluger J et al. Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors or angiotensinII-receptor blockers for ischemic heart disease. Ann Intern Med 2009; 151: 861-871.
11. Braunwald E, Domanski MJ, Fowler SE et al. Angiotensin-convertingenzyme inhibition in stable coronary artery disease. N Engl J Med 2004; 351: 2058-2068.
12. Cohn JN, Tognoni G, Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001; 345: 1667-1675.
13. Fox KM. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362: 782-788.
14. McMurray JJ, Ostergren J, Swedberg K et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003; 362: 767-771.
15. Efrati S, Zaidenstein R, Dishy V et al. ACE inhibitors and survival of hemodialysis patients. Am J Kidney Dis 2002; 40: 1023-1029.
16. Tai DJ, Lim TW, James MT et al. Cardiovascular effects of angiotensin converting enzyme inhibition or angiotensin receptor blockade in hemodialysis: a meta-analysis. Clin J Am Soc Nephrol 2010; 5: 623-630.
17. Zannad F, Kessler M, Lehert P et al. Prevention of cardiovascular events in end-stage renal disease: results of a randomized trial of fosinopril and implications for future studies. Kidney Int 2006; 70: 1318-1324.
18. Abbott K, Trespalacios F, Agodoa L et al. HIVAN and medication use in chronic dialysis patients in the United States: analysis of the USRDS DMMS Wave 2 study. BMC Nephrol 2003; 4: 5.
19. Agarwal R, Sinha AD. Cardiovascular protection with antihypertensive drugs in dialysis patients: systematic review and meta-analysis. Hypertension 2009; 53: 860-866.
20. Heerspink HJ, Ninomiya T, Zoungas S et al. Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: a systematic review and meta-analysis of randomised controlled trials. Lancet 2009; 373: 1009-1015.
21. Brown NJ, Vaughan DE. Angiotensin-converting enzyme inhibitors. Circulation 1998; 97: 1411-1420.
22. Dahlof B, Devereux RB, Kjeldsen SE et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995-1003.
23. Takahashi A, Takase H, Toriyama T et al. Candesartan, an angiotensin II type-1 receptor blocker, reduces cardiovascular events in patients on chronic haemodialysis-a randomized study. Nephrol Dial Transplant 2006; 21: 2507-2512.
24. Suzuki H, Kanno Y, Sugahara S et al. Effect of angiotensin receptor blockers on cardiovascular events in patients undergoing hemodialysis: an open-label randomized controlled trial. Am J Kidney Dis 2008; 52: 501-506.
25. Himmelfarb J, Stenvinkel P, Ikizler TA et al. The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int 2002; 62: 1524-1538.
26. Handelman GJ, Walter MF, Adhikarla R et al. Elevated plasma F2-isoprostanes in patients on long-term hemodialysis. Kidney Int 2001; 59: 1960-1966.
27. Marney AM, Ma J, Luther JM et al. Endogenous bradykinin contributes to increased plasminogen activator inhibitor 1 antigen following hemodialysis. J Am Soc Nephrol 2009; 20: 2246-2252.
28. Horl WH. Hemodialysis membranes: interleukins, biocompatibility, and middle molecules. J Am Soc Nephrol 2002; 13(Suppl 1): S62-S71.
29. Hornig B, Landmesser U, Kohler C et al. Comparative effect of ace inhibition and angiotensin II type 1 receptor antagonism on bioavailability of nitric oxide in patients with coronary artery disease: role of superoxide dismutase. Circulation 2001; 103: 799-805.
30. Erdos EG. Kinins, the long march-a personal view. Cardiovasc Res 2002; 54: 485-491.
31. Pan ZK, Zuraw BL, Lung CC et al. Bradykinin stimulates NF-kappaB activation and interleukin 1beta gene expression in cultured human fibroblasts. J Clin Invest 1996; 98: 2042-2049.
32. Brown NJ, Gainer JV, Murphey LJ et al. Bradykinin stimulates tissue plasminogen activator release from human forearm vasculature through B2 receptor-dependent, NO synthase-independent, and cyclooxygenase-independent pathway. Circulation 2000; 102: 2190-2196.
33. Miyazaki H, Matsuoka H, Itabe H et al. Hemodialysis impairs endothelial function via oxidative stress: effects of vitamin E-coated dialyzer. Circulation 2000; 101: 1002-1006.
34. Chan KE, Lazarus JM, Thadhani R et al. Anticoagulant and antiplatelet usage associates with mortality among hemodialysis patients. J Am Soc Nephrol 2009; 20: 872-881.
35. Chan KE, Lazarus JM, Wingard RL et al. Association between repeat hospitalization and early intervention in dialysis patients following hospital discharge. Kidney Int 2009; 76: 331-341.
36. Chan KE, Lazarus JM, Thadhani R et al. Warfarin use associates with increased risk for stroke in hemodialysis patients with atrial fibrillation. J Am Soc Nephrol 2009; 20: 2223-2233.
37. Teng M, Wolf M, Lowrie E et al. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 2003; 349: 446-456.
38. Rosenbaum PR. Model-based direct adjustment. J Am Stat Assoc 1987; 82: 387-394.
39. Hirano K IG. Estimation of causal effects using propensity score weighting: an application to data on right heart catherization. Health Serv Outcomes Res Methodol 2001; 2: 259-278.
40. Lee SW, Park SW, Yun SC et al. Triple antiplatelet therapy reduces ischemic events after drug-eluting stent implantation: Drug-Eluting stenting followed by Cilostazol treatment REduces Adverse Serious cardiac Events (DECREASE registry). Am Heart J 2010; 159: 284-291.
41. Kramer JM, Curtis LH, Dupree CS et al. Comparative effectiveness of beta-blockers in elderly patients with heart failure. Arch Intern Med 2008; 168: 2422-2428.
42. Park DW, Seung KB, Kim YH et al. Long-term safety and efficacy of stenting versus coronary artery bypass grafting for unprotected left main coronary artery disease: 5-year results from the MAIN-COMPARE (revascularization for unprotected left main coronary artery stenosis: comparison of percutaneous coronary angioplasty versus surgical revascularization) registry. J Am Coll Cardiol 2010; 56: 117-124.
43. Peduzzi P, Concato J, Feinstein AR et al. Importance of events per independent variable in proportional hazards regression analysis II. Accuracy and precision of regression estimates. (Abstract). J Clin Epidemiol 1995; 48: 1503-1510.
44. Imbens G. The role of propensity score in estimating dose-response in observatinoal studies for causal effect. Biometrika 2000; 3: 706-710.